BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China flag China · Delayed Price · Currency is CNY
35.23
-0.89 (-2.46%)
At close: Sep 11, 2026

SHA:688166 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,3481,1901,2481,1611,0131,050
Other Revenue
16.2334.1434.2718.344.042.25
1,3641,2241,2831,1801,0171,052
Revenue Growth
17.38%-4.59%8.73%15.94%-3.33%34.00%
Cost of Revenue
640.27615.41560.51542.9390.95470.07
Gross Profit
724.03608.23722.04636.61626.38582.34
Selling, General & Admin
210.67232.53210.87180.46184.98145.56
Research & Development
337.71304.95297.45248.59207.02173.29
Other Operating Expenses
2.43-0.491.39-1.595.224.22
Operating Expenses
598.11556.67521.27428.37395333.18
Operating Income
125.9251.56200.76208.24231.38249.16
Interest Expense
-72.58-62.96-52.44-44.42-23.71-9.7
Interest & Investment Income
3.945.5510.9617.996.210.14
Currency Exchange Gain (Loss)
-0.366.091.922.612.994.63
Other Non Operating Income (Expenses)
-8.25-2.07-2.14-1.88-2.17-1.77
EBT Excluding Unusual Items
48.67-1.83159.07182.54224.68252.46
Impairment of Goodwill
-3.12-3.12-4.38---
Gain (Loss) on Sale of Investments
13.5-5.54-17.33-15.26-3.390.79
Gain (Loss) on Sale of Assets
-0.28-0.5-0.15-0.25-0.01-0.26
Asset Writedown
-3.44-----
Other Unusual Items
24.5924.8919.9921.7420.934.47
Pretax Income
79.9313.91157.2188.77242.21257.46
Income Tax Expense
-19.85-23.0515.9415.3530.7819.9
Earnings From Continuing Operations
99.7836.95141.26173.42211.43237.56
Minority Interest in Earnings
-3.5117.5647.929.0428.26.39
Net Income
96.2754.51189.17202.47239.62243.95
Net Income to Common
96.2754.51189.17202.47239.62243.95
Net Income Growth
-3.70%-71.18%-6.57%-15.51%-1.77%43.60%
Shares Outstanding (Basic)
415419420422413407
Shares Outstanding (Diluted)
415419420422413407
Shares Change
-1.69%-0.24%-0.34%2.10%1.61%-1.87%
EPS (Basic)
0.230.130.450.480.580.60
EPS (Diluted)
0.230.130.450.480.580.60
EPS Growth
-2.04%-71.11%-6.25%-17.24%-3.33%46.34%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-15.35-128.22-11.64-209-415.47-733.59
Free Cash Flow Per Share
-0.04-0.31-0.03-0.49-1.01-1.80
Dividend Per Share
0.0160.0160.0960.0960.1140.120
Dividend Growth
-83.33%-83.33%0%-15.79%-5.00%42.86%
Gross Margin
53.07%49.71%56.30%53.97%61.57%55.33%
Operating Margin
9.23%4.21%15.65%17.66%22.74%23.67%
Profit Margin
7.06%4.46%14.75%17.16%23.55%23.18%
Free Cash Flow Margin
-1.13%-10.48%-0.91%-17.72%-40.84%-69.71%
EBITDA
277.41195.13298.05275.07271.03283.34
EBITDA Margin
20.33%15.95%23.24%23.32%26.64%26.92%
D&A For EBITDA
151.49143.5797.2866.8339.6534.18
EBIT
125.9251.56200.76208.24231.38249.16
EBIT Margin
9.23%4.21%15.65%17.66%22.74%23.67%
Effective Tax Rate
--10.14%8.13%12.71%7.73%
Revenue as Reported
1,3641,2241,2831,1801,0171,052
Advertising Expenses
-1.692.28-0.521.01